OGI
Organigram Global, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$0.94
+1.73%Year over year
Reported trailing growth
- Revenue
- +38.1%
- EBITDA
- +384.3%
- EBIT
- +67.7%
- EPS
- +1961.9%
- Free cash flow
- -75.1%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +5.0%
- EBITDA
- +170.0%
- EPS
- -92.9%
Three-year CAGR
- Revenue
- +8.5%
- EBITDA
- +57.3%
- EBIT
- -82.4%
- Net income
- +60.9%
- EPS
- +70.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026